Oncorus: The leader in next-generation oncolytic immunotherapies. The company's lead program ONCR-177 is a Ph1 oHSV with complementary payloads (PD1, CCL4, IL12, FLT3, CTLA4) to encourage immune stimulation, with readout guided for 2H21. Secondary programs include intravenously delivered synthetic vRNA immunotherapies (CVA21 and SVV) utilizing a novel liquid nanoparticle (LNP) delivery strategy designed to overcome the challenges caused by neutralizing antibodies.
Based in...
US - New England
Clinical Stage
Phase l or ll
Disease Space
Public, USA
Market Cap
100MM - 500MM
50 Hampshire Street
Suite 401
Cambridge, MA 02139
United States

Company Participants at Oncorus Synthetic Day June 2021

  • Ted Ashburn, CEO

Top 10 Holders of Oncorus, Inc.

Institution OS (%) Position Mkt Val ($MM) Source Filing Date
Deerfield Management Company LP 12.29 3,148,977 32.03 13F 6/30/21
MPM Asset Management LLC 11.12 2,849,464 28.98 13F 6/30/21
MPM Oncology Impact Management LP 9.28 2,377,031 24.17 13F 6/30/21
Citadel LP 7.42 1,900,970 19.33 13F 6/30/21
Citadel Advisors LLC 7.24 1,855,355 18.87 Stakes 3/30/21
CHI Advisors LLC 6.77 1,735,979 17.65 13F 6/30/21
Perceptive Advisors LLC 5.71 1,463,599 14.88 13F 6/30/21
Fosun International Ltd. 3.76 962,321 9.79 13F 6/30/21
Sphera Funds Management Ltd. 3.49 893,548 9.09 13F 6/30/21
BlackRock Fund Advisors 2.93 750,033 7.63 13F 6/30/21
Ownership data is sourced through FactSet.

Stock Market Data

Data is being loaded...
Data is being loaded...
Data is being loaded...
Data is being loaded...
Market Data copyright © 2021 QuoteMedia. Data delayed 15 minutes unless otherwise indicated (view delay times for all exchanges). RT=Real-Time, RTB=Real-Time BATS BZX Price/Quote; not sourced from all markets, RTN=Real-Time NASDAQ Basic+ Price/Quote; not sourced from all markets, EOD=End of Day, PD=Previous Day. Market Data powered by QuoteMedia. Terms of Use.